REPORTING OF ADVERSE EVENTS. The Investigator shall promptly advise the Sponsor of any serious adverse event or unanticipated adverse effect occurring during the Study, or subsequent to the completion or termination of the Study, that becomes known to him.
Appears in 4 contracts
Sources: Clinical Trial Agreement (Oramed Pharmaceuticals Inc.), Clinical Trial Agreement (Oramed Pharmaceuticals Inc.), Clinical Trial Agreement (Brainstorm Cell Therapeutics Inc)